AGL 2033

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: AGL 2033
• 英文别名: 1,2-dimethyl-6-phenyl-imidazo[4,5-g]-quinoxaline；1,2-Dimethyl-6-phenylimidazo[4,5-g]quinoxaline
• 化学式: C₁₇H₁₄N₄
• 分子量: 274.325
• InChiKey: VLKLOAZMKOFHKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1,2-二甲基苯并咪唑 在 palladium on activated charcoal 硫酸 、 氢气 、 硝酸 、 溶剂黄146 作用下， 以 乙醇 、 水 为溶剂， 反应 10.5h， 生成 AGL 2033
  参考文献：
  名称：

  Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit

  摘要：

  Here we report on novel quinoxalines as highly potent and selective inhibitors of the type III receptor tyrosine kinases PDGFR, FLT3, and KIT. These compounds, tricyclic quinoxalines, were generated in order to improve bioavailability over the highly hydrophobic bicyclic quinoxalines. Four of the highly active compounds were characterized in detail and are shown to inhibit PDGFR kinase activity of the isolated receptor as well as in intact cells in the sub-micromolar concentration range. We show that the most active inhibitor (compound 13, AGL 2043) is similar to 15-20 times more potent than its isomer (compound 14, AGL 2044). We therefore compared the three dimensional structures of the two compounds by X-ray crystallography. These compounds are also highly effective in blocking the kinase activity of FLT3, KIT, and the oncogenic protein Tel-PDGFR in intact cells. These compounds are potent inhibitors of the proliferation of pig heart smooth muscle cells. They fully arrest the growth of these cells and the effect is fully reversible. The chemical, biochemical and cellular properties of these compounds as well as the solubility properties make them suitable for development as anti-restenosis and anti-cancer agents. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00048-8

文献信息

• PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
  申请人：Yissum Research Development Company of the Hebrew University of Jerusalem

  公开号：US20020028817A1

  公开（公告）日：2002-03-07

  A preparation of a tyrphostin including a compound of a general formula: 1 wherein, for compound I, the preparation is enriched either for R 6 at position 6 or for R 6 at position 7, or, for Compound II, the preparation is enriched either for R 6 at position 6 or for R 6 at position 8.

  一种包括一般公式为：1的化合物的酪普司汀制备物，其中对于化合物I，制备物在位置6处或位置7处富集R6，或对于化合物II，制备物在位置6处或位置8处富集R6。
• [EN] PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME<br/>[FR] COMPOSES PDGF INHIBITEURS DU RECEPTEUR DE KINASE, LEUR PREPARATION ET LEUR PURIFICATION, ET COMPOSITIONS PHARMACEUTIQUES A BASE DE CEUX-CI
  申请人：YISSUM RES DEV CO

  公开号：WO2001034607A1

  公开（公告）日：2001-05-17

  A preparation of a tyrphostin including a compound of a general formula (Compound I) or (Compound II), wherein, for (Compound I), the preparation is enriched either for R6 at position 6 or for R6 at position 7, or, for (Compound II), the preparation is enriched either for R6 at position 6 or for R6 at position 8.

  一种包括一般式化合物（化合物I）或（化合物II）的tyrphostin制剂，其中对于（化合物I），制剂在位置6处富集R6或在位置7处富集R6，或对于（化合物II），制剂在位置6处富集R6或在位置8处富集R6。
• Liposome formulations
  申请人：OPKO Pharmaceuticals, LLC

  公开号：US10548841B2

  公开（公告）日：2020-02-04

  The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.

  本发明涉及药物制剂，包括抗血管生成化合物，如单克隆抗体或其片段，例如选自抑制血管内皮生长因子作用的血管内皮生长因子粘合剂雷尼珠单抗，以及选自药学上可接受的脂质体的递送剂。这些制剂可用于治疗动物和人的各种血管生成障碍和疾病，优选用于治疗选自年龄相关性黄斑变性、糖尿病性黄斑水肿和角膜新生血管的眼科疾病。
• PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME
  申请人：Yissum Research and Development Company of the Hebrew University of Jerusalem

  公开号：EP1228072A1

  公开（公告）日：2002-08-07
• EP1228072A4
  申请人：——

  公开号：EP1228072A4

  公开（公告）日：2003-05-07